42489-5 |
Aureobasidium pullulans Ab |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Aureobasidium pullulans Ab [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42489-5 |
|
|
|
|
Both |
|
|
|
0 |
A pullulans Ab CSF Ql |
|
|
|
N |
|
A pullulans; ABS; Aby; Antby; Anti; Antibodies; Antibody; Aureobasidm; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; ID; Infectious Disease; InfectiousDisease; m12; Microbiology; Neuro; Neurology; Ordinal; P aureobasidium; P pullulans; Point in time; PR; Pullaria aureobasidium; Pullulan; Pullularia; Pullularia pullulans; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
4249-9 |
Etilefrine |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Etilefrine [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4249-9 |
|
|
|
|
Observation |
|
|
|
0 |
Etilefrine Dose |
|
|
|
Y |
|
AGIT PLUS; Amphodyn; Bioflutin N; Dihydergot plus; Dose med or substance; DRUG DOSES; Effortil plus; Ergolefrin; Ergomimat plus; Ethyladrianol; Ethylnor phenylephrine; Influbene; Poikilton; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
42490-3 |
Blastomyces dermatitidis Ab |
Titr |
Plr fld |
Pt |
SemiQn |
Comp fix |
|
ACTIVE |
Blastomyces dermatitidis Ab [Titer] in Pleural fluid by Complement fixation |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
42490-3 |
|
Comp fix |
|
|
Both |
|
|
|
0 |
B dermat Ab Titr Plr CF |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B dermat; B dermatitidis; Blasto; Blastomycosis; CF; Comp fixation; Compfix; Complement fixation; Dilution factor; Dilution Factor (Titer); ID; Infectious Disease; InfectiousDisease; Lung; Microbiology; Pleural; Pleural fluid; Point in time; Pulmonary; Pulmonology; Random; Respiratory; SmQn; thoracentesis fluid; Titer; Titered; Titre; Ttr |
2.75 |
2.16 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
42491-1 |
Cannabinoids |
PrThr |
Bld |
Pt |
Ord |
Screen |
|
ACTIVE |
Cannabinoids [Presence] in Blood by Screen method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
42491-1 |
|
Screen |
|
|
Both |
|
|
|
0 |
Cannabinoids Bld Ql Scn |
|
|
|
N |
|
Addiction; Blood; Cannabinoid; Delta-9-tetrahydrocannabinol; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Marijuana; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Scn; Scr; Screen; Scrn; THC; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect new model for ordinal terms; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42492-9 |
Carboxy tetrahydrocannabinol |
PrThr |
Bld |
Pt |
Ord |
|
|
ACTIVE |
Carboxy tetrahydrocannabinol [Presence] in Blood |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUG/TOX |
|
42492-9 |
|
|
|
|
Both |
|
|
|
0 |
CarboxyTHC Bld Ql |
|
|
|
N |
|
11-nor-9-carboxy-delta-9-THC; 11-nor-9-carboxy-THC; 11-nor-delta-9-THC-9-COOH; 9-carboxy-11-nor-delta-9-tetrahydrocannabinol; Addiction; Blood; Carboxytetrahydrocannabinol; CarboxyTHC; Carboxy-THC-delta-9; Delta(9)-THC; Delta-9-tetrahydrocannabinol; Delta-9-tetrahydrocannabinol metabolite; Dronabinol; DRUG/TOXICOLOGY; Drugs; Drugs of abuse; Illicit; Marijuana; Nabilone; Ordinal; Point in time; PotentialForAbuse; PR; QL; Qual; Qualitative; Random; Screen; THC; THCA; THCC; THCCOOH; THC-COOH; WB; Whole blood |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The Property has been changed from ACnc to reflect the new model for ordinal terms where results are based on a cut-off value.; The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42493-7 |
Catecholamines.free fractionated |
MCnc |
Plas |
Pt |
Qn |
|
|
ACTIVE |
Catecholamines Free fractionated [Mass/volume] in Plasma |
|
MIN |
DefinitionDescription |
|
|
ug/L |
|
|
|
|
|
|
CHEM |
|
42493-7 |
|
|
|
|
Both |
|
|
|
0 |
FCA Fract Plas-mCnc |
|
|
|
N |
|
Cate; Catec; Catech; Catechol; Catecholamine; Catecholamines.total; Catechols; Chemistry; Epinephrine+norepinephrine+dopamine; FCA; FCA Fract; FR; Frac; Fract; Fraction; Level; Mass concentration; Non-protein bound; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.73 |
2.16 |
|
|
|
|
|
|
|
ug/L |
|
|
|
0 |
42494-5 |
Coccidioides immitis Ab |
Titr |
Plr fld |
Pt |
SemiQn |
Comp fix |
|
ACTIVE |
Coccidioides immitis Ab [Titer] in Pleural fluid by Complement fixation |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
42494-5 |
|
Comp fix |
|
|
Both |
|
|
|
0 |
C immitis Ab Titr Plr CF |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; B immitis; Blastomycoides immitis; C esteriformis; C immitis; CF; Coccidioides esteriformis; Coccidiomycosis; Coccio; Comp fixation; Compfix; Complement fixation; Dilution factor; Dilution Factor (Titer); G immite; G louisianoideum; G metaeuropea; Geotrichum immite; Glenospora metaeuropea; Glenosporum louisianoideum; ID; Infectious Disease; InfectiousDisease; Lung; Microbiology; P esteriformis; P mazzai; Pleural; Pleural fluid; Point in time; Posadasia esteriformis; Pseudococcidioides mazzai; Pulmonary; Pulmonology; Random; Respiratory; San Joaquin Valley fever; SmQn; T proteolyticum; thoracentesis fluid; Titer; Titered; Titre; Trichosporon proteolyticum; Ttr; Valley fever |
2.75 |
2.16 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
42495-2 |
Cytomegalovirus Ab.IgG |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Cytomegalovirus IgG Ab [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42495-2 |
|
|
|
|
Both |
|
|
|
0 |
CMV IgG CSF Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; CMV; Cytomegalo virus; Cytomgal; HHV-5; Human Herpesvirus-5; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42496-0 |
Echinococcus sp Ab |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Echinococcus sp Ab [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42496-0 |
|
|
|
|
Both |
|
|
|
0 |
Echinococcus Ab CSF Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Echinococcosis; ID; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Ordinal; p2; Point in time; PR; QL; Qual; Qualitative; Random; Screen; species; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; spp |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42497-8 |
Epstein Barr virus early Ab |
Titr |
CSF |
Pt |
SemiQn |
|
|
ACTIVE |
Epstein Barr virus early Ab [Titer] in Cerebral spinal fluid |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
42497-8 |
|
|
|
|
Both |
|
|
|
0 |
EBV EA Ab Titr CSF |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Dilution factor; Dilution Factor (Titer); EA; EBV; EBV EA; Epstn; HHV-4; human herpesvirus 4; ID; Infectious Disease; InfectiousDisease; Microbiology; Mono; Mononucleosis; Neuro; Neurology; Point in time; Random; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Titer; Titered; Titre; Ttr |
2.75 |
2.16 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
42498-6 |
Epstein Barr virus nuclear Ab |
Titr |
CSF |
Pt |
SemiQn |
|
|
ACTIVE |
Epstein Barr virus nuclear Ab [Titer] in Cerebral spinal fluid |
|
MAJ |
DefinitionDescription |
|
|
titer |
|
|
|
|
|
|
MICRO |
|
42498-6 |
|
|
|
|
Both |
|
|
|
0 |
EBV NA Ab Titr CSF |
|
|
|
N |
|
ABS; Aby; ANA; ANF; Antby; Anti; Antibodies; Antibody; Antinuclear antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Dilution factor; Dilution Factor (Titer); EBNA; EBV; EBV NA; Epstn; HHV-4; human herpesvirus 4; ID; Infectious Disease; InfectiousDisease; Microbiology; Mono; Mononucleosis; NA; Neuro; Neurology; Nuc; Point in time; Random; SmQn; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Titer; Titered; Titre; Ttr |
2.75 |
2.16 |
|
|
|
|
|
|
|
{titer} |
|
|
|
0 |
42499-4 |
Fibrin D-dimer |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Fibrin D-dimer [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
COAG |
|
42499-4 |
|
|
|
|
Both |
|
|
|
0 |
D Dimer CSF Ql |
|
|
|
N |
|
Cerebral spinal fluid; Cerebrospinal Fl; COAGULATION; D Dimer; Dextro; Fragment D-dimer; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
425-9 |
Pyrazinamide |
Susc |
Isolate |
Pt |
OrdQn |
Agar diffusion |
|
ACTIVE |
Pyrazinamide [Susceptibility] by Disk diffusion (KB) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
425-9 |
|
Agar diffusion |
|
|
Observation |
|
|
|
0 |
PZA Islt KB |
|
|
|
|
|
ANTIBIOTIC SUSCEPTIBILITIES; AST; Disk diffusion; ID; Infectious Disease; InfectiousDisease; Islt; Isol; KB; Kirby-bauer; Point in time; PZA; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty |
2.19 |
1 |
|
|
|
|
|
|
|
|
|
|
|
0 |
4250-7 |
Fencamfamin |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Fencamfamin [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4250-7 |
|
|
|
|
Observation |
|
|
|
0 |
Fencamfamin Dose |
|
|
|
Y |
|
Addiction; Dose med or substance; DRUG DOSES; Drugs of abuse; Fencamfamine; Glucoenergan; Illicit; Point in time; PotentialForAbuse; QNT; Quan; Quant; Quantitative; Random; Reactivan |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |
42500-9 |
Fosamprenavir |
Susc |
Isolate |
Pt |
OrdQn |
Phenotyping |
|
ACTIVE |
Fosamprenavir [Susceptibility] by Phenotype method |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
ABXBACT |
|
42500-9 |
|
Phenotyping |
|
|
Observation |
|
|
|
0 |
Fosamprenavir Islt Phenotyp |
|
|
|
N |
|
908; ANTIBIOTIC SUSCEPTIBILITIES; AST; FPV; GW433908; ID; Infectious Disease; InfectiousDisease; Islt; Isol; Lexiva; Pheno; Phenotype; Phenotypic; Point in time; Random; Sus; Suscept; Susceptibilities; Susceptibility; Susceptibilty; Telzir; Virtual Phenotype |
2.73 |
2.16 |
|
|
|
|
|
|
|
|
|
|
|
0 |
42501-7 |
Glutamate decarboxylase 65 Ab |
ACnc |
CSF |
Pt |
Qn |
|
|
ACTIVE |
Glutamate decarboxylase 65 Ab [Units/volume] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
arb U/mL |
|
|
|
|
|
|
SERO |
|
42501-7 |
|
|
|
|
Both |
|
|
|
0 |
GAD65 Ab CSF-aCnc |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Arbitrary concentration; Autoantibodies; Autoantibody; Autoimmune myelopathy; c707; Cerebral spinal fluid; Cerebrospinal Fl; GAD; GAD65; GAD-65; GADA; Glu; Glutamic acid; Glutamic acid decarboxylase-65; Insulin-Dependent Diabetes Mellitus; Neuro; Neurology; Paraneoplastic neurological syndrome; Point in time; QNT; Quan; Quant; Quantitative; Random; Serology; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.73 |
2.16 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
42502-5 |
Glycolate |
SCnc |
Ser/Plas |
Pt |
Qn |
|
|
ACTIVE |
Glycolate [Moles/volume] in Serum or Plasma |
|
MIN |
DefinitionDescription |
|
|
mmol/L |
|
|
|
|
|
|
CHEM |
|
42502-5 |
|
|
|
|
Both |
|
|
|
0 |
Glycolate SerPl-sCnc |
|
|
|
N |
|
Chemistry; Glycolic acid; Level; Pl; Plasma; Plsm; Point in time; QNT; Quan; Quant; Quantitative; Random; SerP; SerPl; SerPlas; Serum; Serum or plasma; SR; Substance concentration |
2.7 |
2.16 |
|
|
|
|
|
|
|
mmol/L |
|
|
|
0 |
42503-3 |
Hantavirus Ab |
PrThr |
Ser |
Pt |
Ord |
|
|
ACTIVE |
Hantavirus Ab [Presence] in Serum |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42503-3 |
|
|
|
|
Both |
|
|
|
0 |
Hantavirus Ab Ser Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Hanta virus; Hemorrhagic fever with renal syndrome; HFRS; HPS; HTNV; ID; Infectious Disease; InfectiousDisease; Microbiology; Ordinal; Orthohantavirus; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Serum; SNV; SR |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42504-1 |
Hepatitis B virus surface Ab |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Hepatitis B virus surface Ab [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42504-1 |
|
|
|
|
Both |
|
|
|
0 |
HBV surface Ab CSF Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; anti-HBsAg; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; HBs; HBsAB; HBV; HBV surface; Hep; Hep B; Hep Bs; Hepatis; Hepatit; Hepatology; HepB; ID; Infectious Disease; InfectiousDisease; Liver; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Surf |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42505-8 |
Hepatitis B virus surface Ag |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Hepatitis B virus surface Ag [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42505-8 |
|
|
|
|
Both |
|
|
|
0 |
HBV surface Ag CSF Ql |
|
|
|
N |
|
Antigen; Antigens; Australia antigen; Cerebral spinal fluid; Cerebrospinal Fl; HBs; HBsAG; HBV; HBV surface; Hep; Hep B; Hep Bs; Hepatis; Hepatit; Hepatology; HepB; ID; Infectious Disease; InfectiousDisease; Liver; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid; Surf |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42506-6 |
Hepatitis C virus Ab |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Hepatitis C virus Ab [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42506-6 |
|
|
|
|
Both |
|
|
|
0 |
HCV Ab CSF Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; HCV; HCVAB; Hep; Hep C; Hepatis; Hepatit; Hepatology; ID; Infectious Disease; InfectiousDisease; Liver; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42507-4 |
Herpes simplex virus 1 Ab.IgG |
PrThr |
CSF |
Pt |
Ord |
|
|
ACTIVE |
Herpes simplex virus 1 IgG Ab [Presence] in Cerebral spinal fluid |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42507-4 |
|
|
|
|
Both |
|
|
|
0 |
HSV1 IgG CSF Ql |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; Cerebral spinal fluid; Cerebrospinal Fl; Herp splx; Herpes simplex virus type 1; Herpes simplex virus type I; HSV; HSV1; i; ID; Immune globulin G; Immunoglobulin G; Infectious Disease; InfectiousDisease; Microbiology; Neuro; Neurology; Ordinal; Point in time; PR; QL; Qual; Qualitative; Random; Screen; Spinal Fl; Spinal Fld; Spinal Flu; Spinal Fluid |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
42508-2 |
Herpes virus 8 Ab.IgG |
ACnc |
Ser |
Pt |
Qn |
IF |
|
ACTIVE |
Herpes virus 8 IgG Ab [Units/volume] in Serum by Immunofluorescence |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42508-2 |
|
IF |
|
|
Both |
|
|
|
0 |
HHV8 IgG Ser IF-aCnc |
|
|
|
N |
|
ABS; Aby; ACIF; Antby; Anti; Antibodies; Antibody; Anticomplement Immunofluorescence; Arbitrary concentration; Autoantibodies; Autoantibody; FA; Fluorescent antibody; Fluoresent; Herpesvirus; HHV; HHV8; HHV-8; Human herpes virus; ID; IFA; Immune fluorescence; Immune globulin G; Immunoflour; Immunofluor; Immunofluorescence; Immunoglobulin G; Infectious Disease; InfectiousDisease; Kaposi's Sarcoma-Associated Herpesvirus; KSHV; Microbiology; Point in time; QNT; Quan; Quant; Quantitative; Random; Serum; SR; Time Resolved Fluorescence; TRF |
2.69 |
2.16 |
|
|
|
|
|
|
|
[arb'U]/mL |
|
|
|
0 |
42509-0 |
Histoplasma capsulatum Ab |
PrThr |
Plr fld |
Pt |
Ord |
Immune diffusion |
|
ACTIVE |
Histoplasma capsulatum Ab [Presence] in Pleural fluid by Immune diffusion (ID) |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
MICRO |
|
42509-0 |
|
Immune diffusion |
|
|
Both |
|
|
|
0 |
H capsul Ab Plr Ql ID |
|
|
|
N |
|
ABS; Aby; Antby; Anti; Antibodies; Antibody; Autoantibodies; Autoantibody; H capsul; H capsulatum; H farciminosum; Histo; Histopl; Histoplasma farciminosum; Histoplasmos; Histoplasmosis; ID; Imm; Immunodiff; Immunodiffusion; Imun; Imune; Infectious Disease; InfectiousDisease; Lung; Microbiology; Ordinal; Pleural; Pleural fluid; Point in time; PR; Pulmonary; Pulmonology; Ql; Qual; Qualitative; Random; Respiratory; Screen; thoracentesis fluid |
2.56 |
2.16 |
|
|
|
|
|
|
|
|
|
|
The PrThr property is used for LOINC terms whose results are reported using an ordered categorical scale, regardless of whether or not an internal threshold was used to make that determination. This change was approved by the Laboratory LOINC Committee in June 2016. |
0 |
4251-5 |
Fenetylline |
Mass |
Dose |
Pt |
Qn |
|
|
ACTIVE |
Fenetylline [Mass] of Dose |
|
MIN |
DefinitionDescription |
|
|
|
|
|
|
|
|
|
DRUGDOSE |
|
4251-5 |
|
|
|
|
Observation |
|
|
|
0 |
Fenetylline Dose |
|
|
|
Y |
|
7-ethyltheophylline ampetamin; Amfetyline; Captagon; Dose med or substance; DRUG DOSES; Fenethylline; Phenethylline; Point in time; QNT; Quan; Quant; Quantitative; Random |
2.69 |
1 |
|
|
|
|
|
|
|
mg |
|
|
|
0 |